Together, our data might decipher the possible molecular mechanisms, by which Rg1 mitigates CIA-evoked bone destruction, and might make Rg1 a potential novel therapy for bone disorders such as RA and osteoporosis by fine-tuning RANKL-induced osteoclast differentiation and functions. This evidence concerns the gene PPP1R3A and rheumatoid arthritis.